Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

by Kataoka, Yoko , Ionita, Ileana , Silverberg, Jonathan I , Pink, Andrew E , Chu, Chia-Yu , DiBonaventura, Marco , Thaçi, Diamant , Antinew, Jeremias , Bieber, Thomas , Biswas, Pinaki , Simpson, Eric L , Rojo, Ricardo , Zdybski, Jacek , Paul, Carle , Malhotra, Bimal , Zhang, Fan , Valdez, Hernan , Forman, Seth , Sinclair, Rodney

in Acne / Administration, Oral / Adult / Antibodies, Monoclonal, Humanized - adverse effects / Antibodies, Monoclonal, Humanized - therapeutic use / Anxiety / Atopic dermatitis / Clinical trials / Cytokines / Dermatitis / Dermatitis, Atopic - drug therapy / Dosage / Dose-Response Relationship, Drug / Double-Blind Method / Drug dosages / Drug therapy / Eczema / Enzyme inhibitors / Female / Humans / Immunoglobulin A / Immunoglobulin A - blood / Injections, Subcutaneous / Interleukin 13 / Interleukin 4 / Interleukin-4 Receptor alpha Subunit - antagonists & inhibitors / Janus kinase / Janus Kinase 1 - antagonists & inhibitors / Male / Monoclonal antibodies / Nausea / Patients / Placebos / Placebos - therapeutic use / Protein Kinase Inhibitors - administration & dosage / Protein Kinase Inhibitors - adverse effects / Pruritus / Pruritus - drug therapy / Pyrimidines - administration & dosage / Pyrimidines - adverse effects / Severity of Illness Index / Sulfonamides - administration & dosage / Sulfonamides - adverse effects / Topical medication

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

2021

Confirm

Do you wish to request the book?

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

Kataoka, Yoko,

Ionita, Ileana,

Silverberg, Jonathan I,

Pink, Andrew E,

Chu, Chia-Yu,

DiBonaventura, Marco,

Thaçi, Diamant,

Antinew, Jeremias,

Bieber, Thomas,

Biswas, Pinaki,

Simpson, Eric L,

Rojo, Ricardo,

Zdybski, Jacek,

Paul, Carle,

Malhotra, Bimal,

Zhang, Fan,

Valdez, Hernan,

Forman, Seth,

Sinclair, Rodney

2021

Overview

In a trial comparing abrocitinib with placebo and dupilumab, IGA and EASI-75 responses were better with abrocitinib than with placebo at 12 weeks. Itch response at 2 weeks was better with the 200-mg dose of abrocitinib than with dupilumab, but neither abrocitinib dose differed significantly from dupilumab in most other key secondary end-point comparisons at week 16.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Acne

/ Administration, Oral

/ Adult

/ Antibodies, Monoclonal, Humanized - adverse effects

/ Antibodies, Monoclonal, Humanized - therapeutic use

/ Anxiety

/ Atopic dermatitis